CCM
CPRX

Consonance Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Consonance Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-17,875,655
Closed -$94.9M – 38
2019
Q3 		$94.9M Hold
17,875,655
– – 9.39% 2
2019
Q2 		$68.6M Hold
17,875,655
– – 4.86% 6
2019
Q1 		$91.2M Buy
17,875,655
+8,473,338
+90% +$24.9M 5.75% 7
2018
Q4 		$18.1M Buy
9,402,317
+3,357,598
+56% +$9.61M 1.33% 18
2018
Q3 		$22.8M Hold
6,044,719
– – 1.23% 26
2018
Q2 		$18.9M Buy
6,044,719
+1,050,000
+21% +$3.19M 1.22% 23
2018
Q1 		$11.9M Buy
4,994,719
+521,112
+12% +$1.73M 1.09% 21
2017
Q4 		$17.5M Buy
4,473,607
+4,104,309
+1,111% +$13.6M 1.58% 17
2017
Q3 		$931K Buy
+369,298
New +$1.01M 0.1% 19
2016
Q1 		– Sell
-2,888,942
Closed -$7.08M – 23
2015
Q4 		$7.08M Sell
2,888,942
-2,913,943
-50% -$8.35M 0.95% 14
2015
Q3 		$17.4M Buy
5,802,885
+285,000
+5% +$1.23M 2.45% 12
2015
Q2 		$22.8M Buy
5,517,885
+668,015
+14% +$2.66M 2.29% 14
2015
Q1 		$21M Buy
+4,849,870
New +$17.5M 1.91% 17

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Consonance Capital Management's CPRX Position: Q4 2019 in Review

Consonance Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q4 2019, closing a stake of 17,875,655 shares — an estimated $94.9M sold.

Consonance Capital Management first reported a position in CPRX in Q1 2015 and held it in 13 quarters. The position peaked at $94.9M in Q3 2019. 130 funds tracked by Wall St. Rank hold CPRX as of Q4 2019.

  • Consonance Capital Management reported no remaining Catalyst Pharmaceutical position as of Q4 2019 after selling out during the quarter.
  • Consonance Capital Management sold 17,875,655 Catalyst Pharmaceutical shares in Q4 2019, an estimated $94.9M.
  • Consonance Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2015 and held it in 13 quarters.
  • Consonance Capital Management's Catalyst Pharmaceutical position peaked at $94.9M in Q3 2019.
  • 130 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2019.

Based on Consonance Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.